Herniation Disc (GRADE)에 의한 급성 Lumbosacral Radiculalgia에서 Gabapentin 대 위약의 단기 효과 (GRADE)
추간판 탈출증에 의한 급성 요천추 신경근통에 대한 가바펜틴 대 위약의 단기 효과: 전향적, 다심적, 무작위, 통제, 이중 맹검 연구
The study consists in evaluating the analgesic efficacy of Gabapentin versus Placebo in the short term (72h) acute lumbosacral radiculalgia due to disc herniation.
In addition to the usual analgesic treatment, the patient will receive gabapentin or placebo.
During the three days of treatment, an evaluation of the pain and the tolerance will be performed within the two groups: experimental and control.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The objective of the study is to evaluate the analgesic efficacy of GABAPENTIN versus Placebo in 72h for hospitalised patients suffering from acute lumbosacral radiculalgia due to disc herniation.
After signing the consent form, patient's clinical data will be collected and the patient will be allocated to one treatment arm by the randomisation process (ratio 1:1 and stratified on the strong opioid intake).
Two treatment arms are possible :
- Experimental group: GABAPENTINE per os
- DAY1:300 mg
- DAY 2: 600 mg
- DAY3 : 900 mg
- Control group: placebo (same dosage per day as GABAPENTINE).
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Arras, 프랑스
- CH Arras-rheumatology
-
Béthune, 프랑스
- CH Béthune-rheumatology
-
Caen, 프랑스
- CHU Caen-rheumatology
-
Dunkirk, 프랑스
- CH Dunkerque-rheumatology
-
Rouen, 프랑스
- CHU Rouen-rheumatology
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 18 years,
- Radiculalgia or lumboradiculalgia less than 3 months (pain of a lower limb systematized to a radicular territory, possibly associated with lumbar pain),
- Inpatient management for a minimum of 72 hours after inclusion,
- Initial radiculalgia VAS ≥ 4 (moderate to severe pain),
- Concordant disc herniation between clinical symptomatology and imaging (CT or MRI) less than 3 months,
- Written consent signed by the patient,
- Affiliation to a social security system
- For women of childbearing age, use of effective contraception
Exclusion Criteria:
- Motor neurological deficit (≤ 3/5) or cauda equina syndrome (emergency surgical indications),
- Chronic neuropathic pain in the lower limb affected by radiculalgia,
- Lumbar infiltration performed within 72 hours prior to inclusion or unable to be performed after 72 hours,
- Patient already on Gabapentin or Pregabalin, or having taken these treatments in the 7 days prior to inclusion
- Contraindication to Gabapentin (Hypersensitivity to the active substance or to any of the excipients: corn starch, talc, yellow iron oxide, titanium dioxide, sodium lauryl sulfate, gelatin, shellac, propylene glycol, black iron oxide and potassium hydroxide)
- Creatinine clearance < 30ml/min,
- Hemodialysis patient,
- Body weight < 50kgs,
- Transplant patient
- Patient under guardianship or curatorship
- Pregnant or breastfeeding woman
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Gabapentin
GABAPENTIN per os*:
|
The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin. During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed. The patient will have to take the treatment as follows:
다른 이름들:
|
|
위약 비교기: Placebo
PLACEBO:
|
The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made. The patient will have to take the treatment as follows:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Visual Analogical Scale (VAS) for radiculalgia
기간: Day 4
|
Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain between Day 1 (first day) and Day 4, Day 1 corresponding to the first administered dose of the treatment (Gabapentin or Placebo). |
Day 4
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
신경통에 대한 VAS
기간: 7일차
|
7일차
|
|
|
요통에 대한 VAS
기간: 7일차
|
7일차
|
|
|
Rate of patients with at least one adverse event
기간: Day 7
|
Rate of patients with at least one adverse event (all types and grades) between Day 1 and Day 7: According to the National Cancer Institute Common terminology criteria for adverse events (NCI CTCAE) v4.0 |
Day 7
|
|
Change in VAS for lumbalgia
기간: 72 hours
|
Change in VAS between Day 1 and Day 4. |
72 hours
|
|
Responder rate for lumbalgia at Day 4.
기간: Day 4
|
A responder is considered when VAS for low back pain is < 40/100 |
Day 4
|
|
Neuropathic Pain Symptom Inventory (NPSI) scale
기간: Day 7
|
The presence of neuropathic pain will be evaluated by the Neuropathic Pain Symptom Inventory (NPSI) scale. This is a self-questionnaire.The tool evaluates mean pain intensity in the last 24h in a verbal numeric scale from zero (no pain) to 10 (worst imaginable pain). Total pain intensity score may be calculated by the sum of 10 descriptors.Evolution of the NPSI (Neuropathic Pain Symptom Inventory) between Day 1 and Day 4, then between Day 1 and Day 7 |
Day 7
|
|
Dn4 (neuropathic pain screening questionnaire)
기간: Day 7
|
In the Dn4 questionnaire there are 4 questions with 10 items. Answers are yes or not. At the end of the questionnaire each "no" is considered as 0, each "yes" is considered as 1. The total score is 10. When addition of answers is 4 or more the test is considered as positive. |
Day 7
|
|
Number of interdose of anti-nociceptive analgesics
기간: Day 4
|
Number of interdose of anti-nociceptive analgesics between Day 1 and Day 4. |
Day 4
|
|
Rate of patients having used at least one interdose
기간: Day 4
|
Rate of patients having used at least one interdose between Day 1 and Day 4 |
Day 4
|
|
Rate of patients having reduced the associated anti-nociceptive analgesic treatment
기간: Day 7
|
Rate of patients having reduced the associated anti-nociceptive analgesic treatment (decrease in dosage or step or stop) between Day 4 and and Day 7. |
Day 7
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Vincent Ducoulombier, MD, GHICL
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- RC-P0103
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .